The p53 tumor suppressor gene is the most frequently mutated gene in cancer.
Research in our lab focuses on the involvement of tumor suppressive wild type p53 and oncogenic mutant p53 in biological processes that determine cell fate and modulate the emergence and progression of cancer.
We are also interested in the “Hippo” tumor suppressor pathway.
In addition to studying the roles of the p53 and Hippo pathways within the cancer cells, we also aim to elucidate the impact of these pathways on the crosstalk between the cancer cells and their microenvironment, including the immune system.
Eleanor Roosevelt International Cancer Fellowship, 1988
Feher Award, 1993
Member, EMBO, 1995
Abisch-Frankel Prize, 1999
Lombroso Award for Cancer Research 2002
EMET Prize, 2003
NIH MERIT award, 2003
Israel National Academy, 2006
Foreign Associate, American Academy of Arts and Sciences, 2007
Academia Europaea, 2007
Israel Prize, 2008
European Cancer Academy, 2009
President, European Association for Cancer Research (EACR), 2012-2014
International Member, US National Academy of Medicine, 2013
Fellow of the AACR Academy, 2019
International Member, US National Academy of Science